Researchers have identified a previously overlooked protein, PTGES3, as playing a critical role in the progression of advanced prostate cancer, offering a potential new target for therapies aimed at overcoming drug resistance. The discovery, stemming from innovative “glow-tagging” of the androgen receptor (AR), sheds light on how cancer cells maintain AR activity even when faced with treatments like enzalutamide. This breakthrough in prostate cancer research could pave the way for more effective treatments for the most challenging cases of the disease.
The androgen receptor is a key driver of prostate cancer growth, and therapies often focus on blocking its activity. However, cancer cells frequently develop resistance, finding ways to restore AR signaling despite treatment. A team led by Haolong Li, now at Fred Hutchinson Cancer Center, developed a novel system to visualize the AR in real-time within living cells, allowing them to systematically investigate what keeps the receptor active. This “glow-tagging” technique, using a fluorescent reporter, enabled a comprehensive search for genes that regulate AR protein levels.
Using a genome-scale CRISPR screen, the researchers systematically turned down thousands of genes, observing which ones were necessary to maintain stable AR protein levels. Genes that, when suppressed, caused the fluorescent signal to dim were identified as AR regulators. While the screen confirmed known regulators like HOXB13 and GATA2, PTGES3 unexpectedly emerged as a top hit. Prior research had linked PTGES3 to inflammation and steroid receptor chaperoning, but its specific role in prostate cancer remained unclear. The team’s findings, published in Nature, demonstrate that suppressing PTGES3 dramatically reduces AR protein levels, halts cell division, and ultimately leads to cancer cell death.
PTGES3: A Surprising Role in the Nucleus
Traditionally, PTGES3 was believed to function primarily outside the cell nucleus, assisting in the stabilization of steroid receptors in the cytoplasm. However, the research revealed a more complex role. The team discovered that PTGES3 also enters the nucleus, the control center of the cell, where the AR binds to DNA and activates genes that promote tumor growth. This suggests that PTGES3 isn’t simply a support protein. it actively participates in the AR’s function at its target genes.
To understand how PTGES3 influences AR activity within the nucleus, Li collaborated with structural biologist Elizabeth Wasmuth, PhD, at the University of Texas Health at San Antonio. Jasmine Anderson, a trainee in Li’s lab, contributed to the study’s revisions, and interpretation. Through biochemical experiments and structural modeling, they demonstrated that PTGES3 directly binds to the AR, helping it engage with chromatin – an essential step in activating AR-regulated genes. PTGES3 not only stabilizes the AR but also actively supports its function inside the nucleus.
Clinical Data Links PTGES3 to Treatment Resistance
The significance of this discovery extends beyond laboratory models. Analysis of clinical tumor data revealed a strong association between PTGES3 expression and resistance to AR-directed therapies. This suggests that PTGES3 may play a crucial role in the most difficult-to-treat forms of prostate cancer, those that have become resistant to standard treatments like enzalutamide. Enzalutamide, a commonly prescribed medication for advanced prostate cancer, works by blocking the AR, but its effectiveness can be limited by the development of resistance.
The findings also have potential implications for other hormone-driven cancers. Breast cancer and other malignancies rely on similar nuclear receptor pathways, raising the possibility that targeting PTGES3 or similar proteins could be beneficial in a broader range of cancers. Researchers are now exploring this possibility.
A New Avenue for Therapeutic Development
The identification of PTGES3 as an essential AR partner highlights a potential vulnerability in advanced prostate cancer. Many therapy-resistant tumors manage to restore AR signaling through various mechanisms, including amplification, mutation, or splice variants. Because these pathways ultimately converge on maintaining AR activity, targeting a key support factor like PTGES3 could represent a novel therapeutic strategy.
At Fred Hutchinson Cancer Center, Li’s lab is continuing to build on these findings, collaborating with colleagues like prostate cancer biologist Peter Nelson, MD, to translate this biological understanding into new therapeutic opportunities for patients with advanced disease. Nelson holds the Stuart and Molly Sloan Precision Oncology Institute Endowed Chair. The research was supported by the Prostate Cancer Foundation, the Pacific Northwest Prostate Cancer SPORE, the Institute for Prostate Cancer Research, the Mike Slive Foundation for Prostate Cancer Research, grants from the National Institutes of Health, and multiple collaborative research programs focused on improving outcomes for patients with advanced, drug-resistant prostate cancer.
The discovery of PTGES3’s role represents a significant step forward in understanding the complexities of prostate cancer and offers a promising new avenue for developing more effective treatments. Future research will focus on developing drugs that specifically target PTGES3, potentially overcoming resistance and improving outcomes for patients facing this challenging disease.
This research underscores the importance of continued investment in basic science to unravel the intricacies of cancer biology. The next steps involve further preclinical studies to validate PTGES3 as a drug target and to identify potential therapeutic compounds. Share your thoughts on this exciting development in the comments below.
